Protagonist Therapeutics Inc.
WEBMay 13, 2024 · Welcome to Protagonist, a clinical-stage biopharmaceutical company. We strive to improve patients’ lives through the power of peptide drug discovery and development, targeting areas of unmet need across rare and prevalent diseases where treatments are limited or inadequate.
Press Releases - Protagonist Therapeutics Inc.
WEBMay 14, 2024 · Protagonist Therapeutics is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities (NCEs) that can potentially transform existing treatment paradigms in disease areas with significant unmet medical needs.
Protagonist, A Top 1% Biotech, Briefly Breaks Out On Psoriasis …
WEBMay 5, 2023 · Shares of PTGX stock briefly broke out Friday after Protagonist said it plans to soon present new test results for its psoriasis drug. The company is targeting psoriasis with a first-ever ...
Protagonist Therapeutics, Inc. (PTGX) Stock Price, News, Quote ...
WEBFind the latest Protagonist Therapeutics, Inc. (PTGX) stock quote, history, news and other vital information to help you with your stock trading and investing.
J&J to Take Protagonist-Licensed Oral Psoriasis Drug to
WEBJul 5, 2023 · After shares of Protagonist Therapeutics crashed 20% Monday following the presentation of data from JNJ-2113—which J&J licensed from the biotech—subsidiary Janssen confirmed it will advance the oral psoriasis drug to Phase III.
Protagonist Announces Two New Phase 3 ICONIC Studies in …
WEBNov 27, 2023 · Protagonist retains all worldwide development and commercialization rights to rusfertide. More information on Protagonist, its pipeline drug candidates and clinical studies can be found on the...
Takeda pays $300M to license Protagonist drug for blood disorder
WEBFeb 1, 2024 · Protagonist Therapeutics, a biotechnology company focused on peptide drugs, is teaming up with Takeda Pharmaceutical on an experimental, injectable medicine for a rare blood disorder.
Protagonist Reports Positive Results from Phase 1 and Pre-clinical ...
WEBMay 12, 2023 · Protagonist retains all worldwide development and commercialization rights to rusfertide. Positive topline results from the FRONTIER 1 study of JNJ-2113 in moderate-to-severe plaque psoriasis ...
Protagonist Therapeutics is Now Oversold (PTGX) - Nasdaq
WEBJul 3, 2023 · In trading on Monday, shares of Protagonist Therapeutics Inc (Symbol: PTGX) entered into oversold territory, hitting an RSI reading of 21.8, after changing hands as low as $16.65 per share.
Protagonist Therapeutics Earns ‘Buy’ Rating: Promising Clinical ...
WEBFeb 9, 2024 · Tim Chiang has given his Buy rating to Protagonist Therapeutics based on a combination of promising factors surrounding the company’s advancements and strategic partnerships.